Business
Ruvidar More Effective in the Treatment of Herpes than FDA-Approved Treatments
Ruvidar(TM) demonstrates higher efficacy in the treatment of Herpes Simplex Virus, Type 1 versus ...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Ruvidar More Effective in the Treatment of Herpes than FDA-Approved TreatmentsRuvidar(TM) demonstrates higher efficacy in the treatment of Herpes Simplex Virus, Type 1 versus FDA-approved, standard of care treatments Acyclovir and Abreva in a preclinical animal model.Toronto, Ontario--(Newsfile Corp. - April 10, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (\"Theralase®\" or the \"Company\"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that RuvidarTM has been proven more effective in the treatment of Herpes Simplex Virus, Type 1 (\"HSV-1\") versus FDA-approved, standard of care treatments Acyclovir (5%) and Abreva (10% Docosanol) in a preclinical animal model.In the latest Theralase® research, Balb/C mice were infected with human HSV-1 virus on Day 0. On Day 1 post-infection, these mice were treated with either: Acyclovir (5%), Abreva (10% Docosanol) or RuvidarTM (1%).Figure 1. Acyclovir (5%) (5 days of treatment x 5 times per day)To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/2786/247993_d66f50f894f73a8a_001full.jpgFigure 2. Abreva (10% Docosanol) (6 days of treatment x 5 times per day)To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/2786/247993_d66f50f894f73a8a_002full.jpgFigure 3. RuvidarTM (1%) (5 days of treatment x once per day)To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/2786/247993_d66f50f894f73a8a_004full.jpgThe results support the safety and efficacy of topically applied non-light activated Ruvidar® for accelerated healing of cutaneous HSV-1 lesions in a mouse model.Pavel Kaspler, Ph.D., Research Scientist, Theralase®, who conducted the preclinical study stated, \"I have now had the opportunity to conduct my next set of experiments, where I increased the number of daily applications of Acyclovir (5%) and Abreva (10% Docosanol) from once per day to 5 times daily for 5 and 6 days, respectively. In this set of experiments, RuvidarTM (1%) remained at once daily for 5 days. As can be clearly seen...